Dipentum capsules for maintenance of ulcerative colitis remission

Dipentum contains olsalazine sodium, a medicine used to maintain remission in patients with ulcerative colitis who cannot tolerate sulfasalazine. It works by delivering an anti-inflammatory compound directly to the colon, helping to reduce inflammation and prevent flare-ups of the disease.

Dipentum is prescribed to maintain remission in adults with ulcerative colitis, especially in patients intolerant to sulfasalazine.

olsalazine sodium

After oral intake, olsalazine sodium mostly reaches the colon unchanged, where colonic bacteria split it into two molecules of 5-aminosalicylic acid (5-ASA). 5-ASA acts locally in the colon to reduce inflammation by inhibiting pathways that produce inflammatory substances such as prostaglandins and leukotrienes. This targeted action helps control symptoms of ulcerative colitis.

Adults: The recommended dose for maintenance of remission is 1.0 gram per day, taken orally in two divided doses.

Administration Instructions: Take Dipentum capsules with food in evenly divided doses.

Hypersensitivity to olsalazine, other salicylates, or any inactive ingredients in the formulation.

Hypersensitivity: Contraindicated in patients allergic to olsalazine, other salicylates, or any capsule ingredients.

Diarrhea: Approximately 17% of patients report diarrhea, which may lead to treatment withdrawal in 6%. Diarrhea can be dose-related and difficult to distinguish from disease symptoms. Inform your doctor if diarrhea occurs.

Hepatic and Renal Monitoring: Patients with impaired liver or kidney function should be closely monitored, as there have been rare reports of liver and kidney injury.

Severe Allergies and Asthma: Monitor for worsening symptoms.

Carcinogenesis: Animal studies showed rare urinary bladder tumors at very high doses not typical in human use.

Pregnancy Category C: Use only if benefits justify potential fetal risk.

Other Precautions: Use caution in elderly patients and those with pre-existing renal or hepatic disease.

Common side effects (occurred in ≥1% of patients):

• Diarrhea (11.1%)
• Abdominal pain or cramps (10.1%)
• Nausea (5.0%)
• Headache (5.0%)
• Dyspepsia (4.0%)
• Rash (2.3%)
• Fatigue/drowsiness/lethargy (1.8%)
• Bloating (1.5%)
• Depression (1.5%)
• Upper respiratory infection (1.5%)
• Itching (1.3%)
• Anorexia (1.3%)
• Joint pain (4.0%)
• Vomiting, stomatitis, dizziness, insomnia, vertigo, and others have been reported less commonly.

Serious but rare side effects (postmarketing reports):

• Aplastic anemia, pancytopenia
• Hepatotoxicity including hepatitis and liver failure
• Interstitial nephritis and other renal impairments
• Interstitial lung disease
• Angioneurotic edema
• Peripheral neuropathy and paraesthesia

Bleeding Risk: Co-administration with low molecular weight heparins or heparinoids can increase bleeding risk around neuraxial anesthesia. Discontinue salicylates before starting these anticoagulants if possible, or monitor closely.

Warfarin: May increase prothrombin time; monitor anticoagulation status.

6-Mercaptopurine or Thioguanine: Concomitant use may enhance myelosuppression risk. Use lowest effective doses and monitor blood counts carefully.

Varicella Vaccine: Avoid salicylates for six weeks post-vaccination to reduce risk of Reye’s syndrome.

Pregnancy: Category C. Animal studies indicate potential fetal toxicity at high doses. Use only if benefits justify risks.

Lactation: Small amounts of 5-ASA metabolite pass into breast milk; breastfeeding mothers should either avoid Dipentum or discontinue breastfeeding to avoid infant diarrhea.

No human overdoses have been reported. Possible symptoms include nausea, vomiting, and diarrhea. Supportive treatment and monitoring of blood parameters, acid-base balance, liver, and kidney function are recommended. No specific antidote exists.